NCCN 5th Annual Congress on Hematologic Malignancies

 
 
 

The NCCN 5th Annual Congress on Hematologic Malignancies took place on October 8 – 9, 2010, in New York, New York.

 

Treatment of CML continues to progress

Keely McClain Read Article
Published: 11/16/10

Even with a 10-year overall survival (OS) rate of 84%-90%, researchers continue to carry out trials on emerging drugs to try and find therapies that provide a better outlook for patients. According to Susan O’Brien, MD, of MD Anderson Cancer Center, even if a better treatment is available, it will be tough to demonstrate. However, 2 randomized, frontline trials have been published looking at nilotonib vs imatinib and dasatinib vs imatinib, both of which have demonstrated patient benefits. [Read Article]

Infections among hematologic malignancies are changing

Mark Fuerst Read Article
Published: 10/19/10

 Streptococcus viridans
Streptococcus viridans

The spectrum of infections seen among patients with hematologic malignancies, in particular leukemia patients, is changing, said John N. Greene, MD, from the H. Lee Moffitt Cancer Center & Research Institute. Chemotherapy is one of the most common causes of mucositis, which predisposes cancer patients to several infections, including Viridans streptococcus, Candida spp, and Staphylococcus epidermidis. He noted that the incidence of mold and yeast infections is increasing in patients with hematologic malignancies. [Read Article]

New risk model predicts neutropenic complications

Mark Fuerst Read Article
Published: 10/18/10

Blood film showing neutropenia
Blood film showing neutropenia

A new risk model may help predict which cancer patients are at highest risk of neutropenia from myelosuppressive chemotherapy and should receive prophylactic growth factors, according to a presentation at the National Comprehensive Cancer Network 5th Annual Congress on Hematologic Malignancies held in New York, New York. “We can use this as a model to predict the individual patient risk of neutropenic complications,” said Gary Lyman, MD, from the Duke Comprehensive Cancer Center in Durham, NC. [Read Article]

Harvard researchers mine data on hematologic malignancies

Mark Fuerst Read Article
Published: 10/15/10

Red blood cells
Red blood cells

Since 1962, Harvard researchers have gathered an enormous data set to answer questions about clinical practice, said Ephraim Hochberg, MD, from the Massachusetts General Hospital (MGH) Cancer Center in Boston. This includes entries on nearly 38,000 pathology reports, 310,000 clinical notes, and 538,000 medications. Dr Hochberg described the data set at the NCCN 5th Annual Congress on Hematololgic Malignancies held in New York recently. [Read Article]

Sometimes less is more when treating myeloma

Keely McClain Read Article
Published: 10/14/10

Asher Chanan-Khan, MD
Asher Chanan-Khan, MD

When looking at evolving strategies for treating myeloma, sometimes less is more, according to Asher Chanan-Khan, MD, of Roswell Park Cancer Institute in Buffalo, New York.  While reviewing currently available and emerging agents for myeloma, Dr Chanan-Khan questioned whether complete response really matters in myeloma and whether the old dogma still holds that melphalan should be restricted if the intention is to collect stem cells. He delivered his remarks recently at the NCCN 5th Annual Congress on Hematologic Malignancies in New York. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}